Not applicableStudy completedNCT00598728What this trial is testingQuality of Life Among Survivors of Hodgkin LymphomaWho this might be right forHodgkin's Disease Memorial Sloan Kettering Cancer Center 255
Testing effectiveness (Phase 2)Study completedNCT01660451What this trial is testingOpen-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's LymphomasWho this might be right forLymphoma, Non-Hodgkin Bayer 227
Early research (Phase 1)Looking for participantsNCT06801002What this trial is testingTrial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological MalignanciesWho this might be right forSolid Tumor Jabez Bioscience, Inc 25
Early research (Phase 1)Ended earlyNCT04045028What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forMultiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma Genentech, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT01200329What this trial is testingHigh-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's DiseaseWho this might be right forLymphoma M.D. Anderson Cancer Center 81
Early research (Phase 1)Study completedNCT02924402What this trial is testingStudy to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesWho this might be right forB-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia Xencor, Inc. 154
Testing effectiveness (Phase 2)Study completedNCT01339572What this trial is testingClinical And Economic Impact Of Upfront Plerixafor In Autologous TransplantationWho this might be right forNon-Hodgkin's LymphomaMultiple Myeloma University of Florida 72
Not applicableLooking for participantsNCT03375619What this trial is testingLong-term Follow-up Study of Patients Receiving CAR-T CellsWho this might be right forChronic Lymphocytic LeukemiaLymphomas Non-Hodgkin's B-CellLymphoma, Small Lymphocytic+6 more Medical College of Wisconsin 500
Not applicableLooking for participantsNCT06508775What this trial is testingLong-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesWho this might be right forMelanoma Stage IIIB-cell Non Hodgkin LymphomaPediatric ALL+4 more Miltenyi Biomedicine GmbH 40
Testing effectiveness (Phase 2)Ended earlyNCT00112723What this trial is testingFlavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaWho this might be right forAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+25 more National Cancer Institute (NCI) 46
Not applicableStudy completedNCT00476229What this trial is testingThymoglobulin and Total Lymphoid Irradiation for Hematologic MalignanciesWho this might be right forLymphomaLeukemia M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03277729What this trial is testingA Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasWho this might be right forRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+20 more Fred Hutchinson Cancer Center 53
Testing effectiveness (Phase 2)Looking for participantsNCT07519772What this trial is testingA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Who this might be right forLymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse Merck Sharp & Dohme LLC 280
Early research (Phase 1)Active Not RecruitingNCT03434769What this trial is testingAntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaWho this might be right forNon-Hodgkin Lymphoma Benjamin Tomlinson 31
Testing effectiveness (Phase 2)Ended earlyNCT00372905What this trial is testingPhase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaWho this might be right forLymphoma Northwestern University 18
Early research (Phase 1)Study completedNCT01969695What this trial is testingAn Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's LymphomaWho this might be right forNon-Hodgkin's Lymphoma AbbVie 11
Testing effectiveness (Phase 2)Looking for participantsNCT05092451What this trial is testingPhase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesWho this might be right forB-Cell LymphomaMyelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)+7 more M.D. Anderson Cancer Center 80
Testing effectiveness (Phase 2)Ended earlyNCT00274651What this trial is testingA Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell LymphomasWho this might be right forCutaneous T-Cell LymphomaPeripheral T-Cell LymphomaNon-Hodgkin's Lymphoma Valerio Therapeutics 53
Large-scale testing (Phase 3)Ended earlyNCT00920153What this trial is testingThree Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin LymphomaWho this might be right forLymphoma French Innovative Leukemia Organisation 442
Testing effectiveness (Phase 2)Ended earlyNCT00301795What this trial is testingRituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaWho this might be right forStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular Lymphoma+3 more National Cancer Institute (NCI) 52